行情

NURO

NURO

NeuroMetrix
NASDAQ

实时行情|Nasdaq Last Sale

3.890
-0.010
-0.26%
盘后: 4.000 +0.11 +2.83% 19:05 11/21 EST
开盘
3.900
昨收
3.900
最高
3.925
最低
3.395
成交量
14.55万
成交额
--
52周最高
13.80
52周最低
2.518
市值
380.51万
市盈率(TTM)
-0.0520
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NURO 新闻

  • 梅西百货同店销售两年来首现下滑 Q3净利润大降97%
  • 新浪财经.6小时前
  • 美国有线电视教父:苹果将在流媒体之战中大放异彩
  • 新浪美股.6小时前
  • 美众议长佩洛西:美墨加贸易协定正取得进展
  • 新浪财经.7小时前
  • 道明证券:明年美联储票委"换血"或强化降息两次预期
  • 新浪美股.8小时前

更多

所属板块

医疗设备、用品及经销
-0.23%
医疗设备和用品
+0.17%

热门股票

名称
价格
涨跌幅

NURO 简况

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
展开

Webull提供Neurometrix Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。